STI Innowacyjne Technologie Laboratoryjne Choose the language:
English Version  Wersja polska
  Homepage » Catalog » 2019 Novel Coronavirus » L1710
Submit to our newsletter:

  • Dostawcy
Anti-COVID-19 Compound Library

Numer kat.L1710
Opis produktu:
In order to respond to the outbreak of pneumonia caused by a novel coronavirus COVID-19, global scientific research institutions and pharmaceutical companies are stepping up related vaccine development and antiviral drug trials. Scientists from multiple countries are working hard to identify drug candidates that can be used for clinical therapy to patients with 2019-nCoV infected pneumonia by screening compound libraries. TargetMol as a drug screen expert quickly generated this compound library by carefully selecting 223 compounds that have been demonstrated to have anti-coronavirus activity and some of them are broad-spectrum antiviral agents including Lopinavir/Ritonavir, Chloroquine diphosphate (combination use with Remdesivir), Polydatin (bind with Mpro), etc. We also will keep updating it in response to the newest research progress. Product Description A unique collection of 223 compounds with anti-coronavirus activity and part of them are broad-spectrum antiviral agents; Compounds contain , Lopinavir/Ritonavir, Chloroquine diphosphate (combination use with Remdesivir), Polydatin (bind with Mpro), etc.; Detailed compound information with structure, target, and biological activity description; NMR and HPLC validated to ensure high purity and quality. The compound library can be highly customized. You can select compounds, quantities, format (dry/solid or DMSO), plate map, and concentration to meet your specific requirement. Please check our Compound Library Instructions for more information. Packaging and Storage Powder or pre-dissolved DMSO solutions in 96 well plate with optional 2D barcode Shipped with dry ice.
 Product Size
Ilość w opakowaniu

This product was added to our catalog on wtorek 14 kwietnia, 2020.

Copyright © 2012 STI
Created by